A Multicenter, Randomized, Active-comparator-controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of a Single Subcutaneous Injection of SHR-2004 in Patients Undergoing Elective Unilateral Total Knee Arthroplasty
Latest Information Update: 24 Jan 2025
At a glance
- Drugs SHR-2004 (Primary) ; Enoxaparin sodium
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Sponsors Beijing Suncadia Pharmaceuticals
Most Recent Events
- 20 Jan 2025 Status changed from recruiting to completed.
- 20 Apr 2023 Status changed from not yet recruiting to recruiting.
- 07 Mar 2023 New trial record